布地格福联合无创正压通气治疗睡眠呼吸障碍并慢阻肺的临床研究

Clinical Study of Budesonide Combined with Noninvasive Positive Pressure Ventilation in the Treatment of Sleep Disordered Breathing and Chronic Obstructive Pulmonary Disease

目的:探讨布地格福联合无创正压通气治疗睡眠呼吸障碍并慢阻肺的临床价值。方法:选取2021年8月—2022年9月我院诊治的睡眠呼吸障碍并慢阻肺患者88例作为研究对象,根据1∶1随机掷骰子原则分为布地格福组44例与对照组44例。对照组给予无创正压通气治疗,布地格福组在对照组治疗基础上给予布地格福治疗,比较两组治疗效果、不良反应发生率、肺功能、动脉血血氧饱和度。结果:治疗2周后,布地格福组总有效率高于对照组,不良反应发生率低于对照组(P<0.05);布地格福组FEV1和FEV1/FVC值、SaO2高于对照组(P<0.05)。结论:布地格福联合无创正压通气治疗睡眠呼吸障碍并慢阻肺能提高患者的治疗效果,降低不良反应发生率,改善肺功能,提高动脉血血氧饱和度。

Objective:To explore the clinical value of budesonide combined with non-invasive positive pressure ventilation in the treatment of sleep disordered breathing and chronic obstructive pulmonary disease.Methods:From August 2021 to September 2022,88 patients with sleep-disordered breathing and chronic obstructive pulmonary disease diagnosed and treated in our hospital were selected as the research objects.According to the principle of 1∶1 random roll of dice,they were divided into 44 patients in the budesonide group and 44 patients in the control group.The control group was treated with noninvasive positive pressure ventilation,and the budesonide group was treated with budesonide on the basis of the control group.The therapeutic effect,incidence of adverse reactions,lung function and arterial blood oxygen saturation were compared between the two groups.Results:After 2 weeks of treatment,the total effective rate of the budesonide group was higher than that of the control group,and the incidence of adverse reactions was lower than that of the control group(P<0.05).The FEV1 and FEV1/FVC values and SaO2 in the budesonide group were higher than those in the control group(P<0.05).Conclusion:The treatment of sleep disordered breathing and chronic obstructive pulmonary disease with noninvasive positive pressure ventilation can improve the therapeutic effect of patients,reduce the incidence of adverse reactions,improve lung function,and increase arterial blood oxygen saturation.